KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Net Income (2016 - 2025)

Historic Net Income for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $137.9 million.

  • West Pharmaceutical Services' Net Income rose 439.06% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.2 million, marking a year-over-year decrease of 90.98%. This contributed to the annual value of $478.0 million for FY2024, which is 1697.06% down from last year.
  • As of Q3 2025, West Pharmaceutical Services' Net Income stood at $137.9 million, which was up 439.06% from $126.8 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Net Income registered a high of $183.0 million during Q2 2022, and its lowest value of $86.4 million during Q1 2025.
  • For the 5-year period, West Pharmaceutical Services' Net Income averaged around $137.5 million, with its median value being $134.3 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first soared by 12075.72% in 2021, then plummeted by 3243.06% in 2022.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Net Income stood at $147.7 million in 2021, then plummeted by 32.43% to $99.8 million in 2022, then surged by 33.97% to $133.7 million in 2023, then dropped by 4.19% to $128.1 million in 2024, then increased by 7.65% to $137.9 million in 2025.
  • Its Net Income stands at $137.9 million for Q3 2025, versus $126.8 million for Q2 2025 and $86.4 million for Q1 2025.